Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032294 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL1817183 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL3713847 | 0.95 | NPBWR1 (0.54) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL3713849 | 0.95 | NPBWR1 (0.54) | CYP1A2CYP2C19CCR2NPBWR1MCHR1 | |
| SCHEMBL5702015 | 0.90 | S1PR5 (0.46) | CCR2NPBWR1MCHR1GAACD274 | |
| SCHEMBL5701943 | 0.90 | S1PR5 (0.46) | CCR2NPBWR1MCHR1GAACD274 | |
| SCHEMBL2587055 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP2C19MCHR1SPHK1SMN1; SMN2 | |
| SCHEMBL1819248 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP2C19MCHR1SPHK1SMN1; SMN2 | |
| SCHEMBL1972076 | 0.87 | CYP1A2 (0.60) | CYP1A2CYP2C19MCHR1SPHK1SMN1; SMN2 | |
| SCHEMBL7781292 | 0.86 | CYP1A2 (0.50) | CYP1A2CYP2C19SPHK1SMN1; SMN2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CYP1A2 130/4885CYP2C19 186/4885CCR2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.